KR20250026153A - Ikzf2 분해제 및 이의 용도 - Google Patents
Ikzf2 분해제 및 이의 용도 Download PDFInfo
- Publication number
- KR20250026153A KR20250026153A KR1020247035795A KR20247035795A KR20250026153A KR 20250026153 A KR20250026153 A KR 20250026153A KR 1020247035795 A KR1020247035795 A KR 1020247035795A KR 20247035795 A KR20247035795 A KR 20247035795A KR 20250026153 A KR20250026153 A KR 20250026153A
- Authority
- KR
- South Korea
- Prior art keywords
- carbocyclyl
- alkyl
- compound
- heterocyclyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323792P | 2022-03-25 | 2022-03-25 | |
| US63/323,792 | 2022-03-25 | ||
| US202363446105P | 2023-02-16 | 2023-02-16 | |
| US63/446,105 | 2023-02-16 | ||
| PCT/US2023/016177 WO2023183540A1 (en) | 2022-03-25 | 2023-03-24 | Ikzf2 degraders and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250026153A true KR20250026153A (ko) | 2025-02-25 |
Family
ID=86185384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247035795A Pending KR20250026153A (ko) | 2022-03-25 | 2023-03-24 | Ikzf2 분해제 및 이의 용도 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250215012A1 (enExample) |
| EP (1) | EP4499649A1 (enExample) |
| JP (1) | JP2025512805A (enExample) |
| KR (1) | KR20250026153A (enExample) |
| CN (1) | CN119731179A (enExample) |
| TW (1) | TW202341988A (enExample) |
| WO (1) | WO2023183540A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| EP4471033A4 (en) * | 2022-01-29 | 2026-03-25 | Gan & Lee Pharmaceuticals Co Ltd | CEREBLON UBIQUITIN LIGASE E3 INHIBITOR |
| CN117065022A (zh) * | 2022-05-17 | 2023-11-17 | 海创药业股份有限公司 | 一种治疗三阴乳腺癌的药物 |
| WO2025261456A1 (zh) * | 2024-06-19 | 2025-12-26 | 甘李药业股份有限公司 | 一种雌激素受体蛋白降解靶向嵌合体化合物及其应用 |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| WO2026139085A1 (zh) * | 2024-12-27 | 2026-07-02 | 甘李药业股份有限公司 | 酪蛋白激酶1α(CK1α)分子胶降解剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021087093A1 (en) * | 2019-10-30 | 2021-05-06 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| EP4168007A1 (en) * | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) * | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
-
2023
- 2023-03-24 TW TW112111194A patent/TW202341988A/zh unknown
- 2023-03-24 US US18/849,594 patent/US20250215012A1/en active Pending
- 2023-03-24 EP EP23719521.9A patent/EP4499649A1/en active Pending
- 2023-03-24 WO PCT/US2023/016177 patent/WO2023183540A1/en not_active Ceased
- 2023-03-24 JP JP2024556604A patent/JP2025512805A/ja active Pending
- 2023-03-24 CN CN202380041783.5A patent/CN119731179A/zh active Pending
- 2023-03-24 KR KR1020247035795A patent/KR20250026153A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250215012A1 (en) | 2025-07-03 |
| JP2025512805A (ja) | 2025-04-22 |
| EP4499649A1 (en) | 2025-02-05 |
| TW202341988A (zh) | 2023-11-01 |
| WO2023183540A1 (en) | 2023-09-28 |
| CN119731179A (zh) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI841200B (zh) | 雜環類化合物、藥物組成物及其應用 | |
| CN112166110B (zh) | Shp2磷酸酶抑制剂及其使用方法 | |
| EP4499649A1 (en) | Ikzf2 degraders and uses thereof | |
| KR20250135228A (ko) | Vav1의 표적 분해 | |
| KR102317480B1 (ko) | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| JP2024527570A (ja) | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 | |
| WO2020103896A1 (en) | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof | |
| US20250195484A1 (en) | Cereblon ligands and uses thereof | |
| BR112020003373B1 (pt) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona, usos dos mesmos e composição farmacêutica | |
| KR20190017030A (ko) | Dnmt1의 억제제로서의 치환된 피리딘 | |
| KR20180100214A (ko) | 안드로겐 수용체 길항제로서의 치환된 티오히단토인 유도체 | |
| KR20140032383A (ko) | Pi3k p110 델타에 대하여 선택적인 벤즈옥사제핀 화합물 및 이의 사용 방법 | |
| JP2025510834A (ja) | Ｉｋｚｆ２分解剤としての二環式ヘテロアリール含有化合物 | |
| WO2024192064A1 (en) | Compounds and compositions as smarca2/4 degraders and uses thereof | |
| AU2017287919A1 (en) | Benzodioxane derivatives and their pharmaceutical use | |
| JP2025526290A (ja) | エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体 | |
| US10961238B2 (en) | Modulators of hedgehog (Hh) signaling pathway | |
| US20240034731A1 (en) | Aza-quinazoline compounds and methods of use | |
| KR20230035437A (ko) | 7-치환된 1-아릴-나프티리딘-3-카르복실산 아미드 및 그의 용도 | |
| WO2023201012A1 (en) | Ikzf2 degraders and uses thereof | |
| WO2024064316A1 (en) | Compounds and compositions as smarca2/4 inhibitors and uses thereof | |
| US20250171467A1 (en) | Fused pyrazole amide analogs as glucosylceramide synthase inhibitors | |
| HK40123006A (en) | Ikzf2 degraders and uses thereof | |
| HK40123004A (en) | Bicyclic heteroaryl-containing compounds as ikzf2 degraders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |